調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

ナノメディシンの世界市場2015-2025

◆タイトル：Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025
◆商品コード：VGAIN5100107
◆調査・発行会社：visiongain
◆発行日：2015年9月
◆ページ数：131
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single UserGBP1,799 ⇒換算￥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算￥449,850見積依頼/購入/質問フォーム
Site License（全社内共有可）GBP4,999 ⇒換算￥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、ナノメディシンの世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・ナノメディシンの世界市場
　（市場規模予測、市場の成長要因・阻害要因など）
・ナノメディシンの世界市場：主要製品別分析
・ナノメディシンの地域別市場分析、市場規模予測
・ナノメディシンの研究開発動向
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Nanopharma – Discover Revenue Prospects Now, Benefiting Your Authority
Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.

Visiongain’s study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.

Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.

Please read on to explore what drives and shapes that industry, also seeing revenue prediction.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.

With that study you assess clinical, technological and commercial trends, results and potentials:
• Why will the nanopharma market expand fast – and what future revenues are possible?
• When will that worldwide industry achieve overall sales in hundreds of billion dollars?
• What products give the most promise for developers, producers and sellers?
• Who are the best-placed companies in that healthcare industry from 2015?
• Where are the most lucrative regions for selling those medicines?
• How will nanotechnological advances affect drug developers, marketers and manufacturers?

Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.

That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Predictions for that world market and submarkets – what sales growth is possible?
Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets:
• Cancer
• Cardiovascular disorders
• Central nervous system (CNS) conditions
• Infectious diseases
• Inflammation
• Other applications of nanotechnology in pharmacotherapy.

Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.

The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Forecasting of leading products’ sales – what revenues are possible for nanodrugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands:
• Abraxane
• Alimta
• Eligard
• Copaxone
• Rapamune
• Neulasta
• Cimzia.

Our sales predictions also cover these products:
• AmBisome
• MIRCERA
• Pegasys
• Emend
• Renagel
• Ritalin.

That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, R&D, competitors and opportunities.

Discover what the future holds. Our study also divides its overall world forecast into geographical segments.

Regional markets for nanomedicine – where will highest sales and growth occur?
Developments worldwide will influence the nano-enabled drugs market, raising demand for those therapies in developed and developing countries. Discover what success is possible.

Our analyses show you individual revenue forecasts to 2025 for five regional markets:
• United States
• Japan
• European Union
• Asia Pacific
• Rest of world.

There you discover progress and outlooks. You assess the nanomedical industry’s future – needs, developments, demands and their meaning. Our work explains, exploring issues affecting nanotechnological companies, influencing their work, results and potentials.

Forces affecting the nanopharma business – what shapes its present and future?
Our new report discusses pressures, opportunities and other events affecting the nanopharmaceutical industry and market from 2015, including these influences:
• Prominent nanomedicine companies by region – leading players
• Systems used in nanotechnology-enabled drug delivery
• Applications in therapeutics, implants, diagnostics and theranostics
• Nanoparticles – liposomes, polymers, quantum dots, superparamagnetic iron oxide (SPIO), carbon nanotubes and nanoshells
• Nanoparticle function, targeting, surface conjugation, improved bioavailability, tunability and controlled release systems
• Investments, infrastructure, networks and collaborations, as well as outlooks for regulatory guidelines and harmonisation.

Our survey also discusses research and development in nanomedicine, in particular for these product candidates:
• DermaVir (Genetic Immunity)
• CRLX101 (Cerulean Pharma)
• CPX-351 (Celator Pharma)
• NC-6004 (NanoCarrier)
• NK-105 (Nippon Kayaku)
• NK-012 (Nippon Kayaku)
• SGT-53 (SynerGene Therapeutics)
• BIND-014 (BIND Biosciences)
• ThermoDox (Celsion)
• ADI-PEG 20 (Polaris).

You assess the nanomedicine industry’s strengths, weaknesses, opportunities and threats. That way you explore what restricts and stimulates companies, seeing what is possible.

Avoid falling behind. With our investigation you discover what the future holds for nano-enabled drugs, seeing prospects for their designers, producers and sellers.

Leading companies and overall 2017 revenue prediction
From 2015, product launches using nanotechnology hold great potential for investments, demand and sales. Our study predicts the world market for nanopharmaceuticals will reach $130bn in 2017, with strong revenue expansion from 2015 to 2025. Explore the potentials.

Our work assesses nanopharma technologies, products and companies holding the best prospects. You see what is possible for technological advances and revenue expansion.

Those analyses cover these companies and other developers, producers, marketers and technology suppliers:
• Sanofi
• BIND Therapeutics
• Merck
• Pfizer
• Cerulean Pharma
• Selecta Biosciences.

And you assess these nanopharma specialists, among others:
• Nanobiotix
• Magforce
• Celgene
• Celsion Corporation
• Nanocarrier.

You also examine three interviews with authorities in these organisations:
• Swiss Federal Laboratories for Materials Science and Technology
• Rexahn Pharmaceuticals
• Cristal Therapeutics.

From 2015 there will arise many opportunities. Our work shows you commercial possibilities for those novel drug technologies, helping you stay ahead in knowledge and succeed.

Ways Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 helps
In the following main ways, our investigation helps your research, analyses, decisions, proposals and presentations:
• Revenues for nanopharma to 2025 at overall world level and for 6 submarkets and 13 products – find outlooks for R&D, production and sales
• Forecasts to 2025 for 5 regional markets – assess leading countries and regions for potential revenues, seeing what progress is possible
• Prospects for established competitors and rising companies – explore portfolios, results, strategies, technologies and outlooks for success
• Analysis of what encourages and restrains the nanomedicine industry – investigate challenges, strengths and competition affecting revenues and profits
• Interviews with authorities – discover what other experts think, say and do, helping you stay ahead in technological, medical and commercial insight.

That study – by visiongain’s in-house analysts in the UK – gives knowledge to help your work, to spare you hassle and save time. You gain data leading companies depend on.

【レポートの目次】

1. Report Overview
1.1 Overview of the Nanomedicine Industry and Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Nanomedicine
2.1 Nanotechnology – Definition
2.2 Nanomedicine – Size Should Not be the Main Definition
2.3 Nanotechnology – Solutions and Improvements in Medicine
2.4 Nanomedicine – Types of Applications
2.4.1 Drug Delivery
2.4.2 Nanodrugs
2.4.2.1 Nanoparticles – Combinations of Three Dimensions
2.4.2.1.1 Liposomes
2.4.2.1.2 Polymers
2.4.2.1.3 Quantum Dots
2.4.2.1.4 Superparamagnetic Iron Oxide (SPIO)
2.4.2.1.5 Carbon Nanotubes
2.4.2.1.6 Carbon Nanoshells
2.4.2.2 Nanoparticle Functionalisation
2.4.2.2.1 Targeting
2.4.2.2.2 Surface Conjugation
2.4.2.2.3 Improved Bioavailability
2.4.2.2.4 Tunability
2.4.2.2.5 Controlled Release
2.4.3 Implants
2.4.4 Diagnostics
2.4.4.1 Diagnostic Tools
2.4.4.2 Medical Instruments
2.4.4.3 Imaging Tools
2.4.4.4 Theranostics

3. Global Nanomedicine Market, 2015-2025
3.1 Revenue Forecasts of Nanomedicine by Therapeutic Area
3.1.1 Forecast of Nanomedicine for Oncology 2015-2025
3.1.2 Forecast of Nanomedicine for Cardiovascular Uses 2015-2025
3.1.3 Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025
3.1.4 Forecast of Nanomedicine for Neurology 2015-2025
3.1.5 Forecast of Nanomedicine for Anti-Infective 2015-2025
3.1.6 Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025

4. Nanomedicine Products – Commercial Outlooks from 2015
4.1 Nanomedicine Products – Segmentation
4.1.1 Nanomedicine Products in the Market – Revenue Potentials, 2015-2025
4.1.1.1 Abraxane (Celgene)
4.1.1.2 Doxil (Janssen)
4.1.1.3 Myocet (Teva Pharmaceuticals)
4.1.1.4 ONCASPAR (Baxalta)
4.1.1.5 Alimta (Eli Lilly)
4.1.1.6 Eligard (Sanofi)
4.1.1.7 DaunoXome (Galen)
4.1.1.8 Copaxone (Teva)
4.1.1.9 Rapamune (PF Prism)
4.1.1.10 Neulasta (Amgen)
4.1.1.11 Cimzia (UCB)
4.1.1.12 AmBisome (Astellas Pharma)
4.1.1.13 MIRCERA (Roche)
4.1.1.14 Pegasys (Roche)
4.1.1.15 Emend (Merck)
4.1.1.16 Renagel (Genzyme)
4.1.1.17 Ritalin (Novartis)

5. Leading National Markets, 2015-2025
5.1 Nanomedicine – Leading Markets, 2014
5.2 The US Nanomedicine Market, 2015-2025
5.3 The Japanese Nanomedicine Market, 2015-2025
5.4 The EU Nanomedicine Market, 2015-2025
5.5 The Asia-Pacific Nanomedicine Market, 2015-2025
5.6 Rest of the World Nanomedicine Market, 2015-2025

6. Profiles of Pharmaceutical Companies with Nanotechnology Related Applications
6.1 Sanofi
6.2 BIND Therapeutics
6.3 Merck
6.4 Pfizer
6.5 Cerulean Pharma
6.6 Selecta Biosciences
6.7 Nanobiotix
6.8 Magforce
6.9 Celgene
6.10 Celsion Corporation
6.11 Nanocarrier

7. Research & Development
7.1 Nanoparticles and Nano-enabled Drugs in the Pipeline
7.1.1 DermaVir (Genetic Immunity)
7.1.2 CRLX101 (Cerulean Pharma)
7.1.3 CPX-351 (Celator Pharma)
7.1.4 NC-6004 (NanoCarrier Co.)
7.1.5 NK-105 (Nippon Kayaku Co. Ltd.)
7.1.6 NK-012 (Nippon Kayaku Co. Ltd.)
7.1.7 SGT-53 (SynerGene Therapeutics)
7.1.8 BIND-014 (BIND Biosciences)
7.1.9 ThermoDox (Celsion)
7.1.10 ADI-PEG 20 (Polaris)

8. Qualitative Analysis of the Nanomedicine Market, 2015
8.1 Room for Improvement
8.1.1 Safety and Toxicology Often Yet to be Determined
8.1.2 Establishment of Structures and Collaborations
8.1.3 Regulatory – The Need for Clear Guidelines and Harmonization

9. Research Interviews, 2015
9.1 Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology
9.1.1 Connecting the Key Players in the Nanomedical Sector in Europe
9.1.2 Nanomedicine Industry in Europe – In Need of an Infrastructure
9.1.3 EU-NCL: Bridging the Major Gaps and Challenges
9.2 Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals
9.2.1 Precision-Targeted Therapy – Revolutionizes Cancer Treatment
9.2.2 RX-21101 – Included in NCL’s Preclinical Characterization Program
9.2.3 Rexahn’s NPDCS Technology – Next Generation Approach to Chemotherapy
9.2.4 Rexahn’s Polymer-Drug Conjugate – Improves Efficacy and Reduces Side Effects
9.3 Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands
9.3.1 Nanomedicine Industry in Europe
9.3.2 CriPec Based Nanomedicines – Overcome the Drawbacks of Conventional Therapies
9.3.3 CriPec Platform – All the Best Features in a Single System
9.3.4 CriPec Docetaxel – Lead Candidate Product
9.3.5 In Development – CriPec Actively Targeted Nanoparticles Platform
9.3.6 Competitive Advantage Can be Achieved Through Partnering of Parties

10. Conclusions of the Research and Analysis
10.1 Nanotechnology Holds Great Promise in Healthcare
10.2 More Research Needed to Establish Safety
10.3 Harmonization in Definition and Guidelines

Table 1.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 2.1 Advantages of Nanotechnology in Medicine
Table 2.2 Challenges and Solutions - NDDS
Table 3.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.2 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.1 Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.2 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.3 Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.4 Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.5 Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.6 Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.7 Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.8 AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.9 MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.10 Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.11 Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.12 Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 4.13 Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.1 Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025
Table 5.2 Nanomedicine Market Share(%) by Leading Regions, 2014-2025
Table 5.3 Prominent Nanomedicine Companies in the US, 2014
Table 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.7 Prominent Nanomedicine Companies in the UK, 2014
Table 5.8 Prominent Nanomedicine Companies in Germany, 2014
Table 5.9 Prominent Nanomedicine Companies in France, 2014
Table 5.10 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 5.11 RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015

Figure 1.1 Nanomedicine - Segmented by Application
Figure 2.1 Applications of Nanotechnology in Diagnostics
Figure 2.2 Applications of Nanotechnology in Therapeutics
Figure 2.3 Systems Used in Nanotechnology-enabled Drug Delivery
Figure 2.4 Market Shares of NDDS by System, 2014
Figure 2.5 NDDS: Market Drivers and Restraints, 2015-2025
Figure 2.6 Representation of Nanoparticles
Figure 2.7 Combinations of Layers that Form Nanoparticles
Figure 2.8 Nanoparticles: Market Drivers and Restraints 2015-2025
Figure 2.9 Implants: Market Drivers and Restraints, 2015-2025
Figure 2.10 Diagnostics: Market Drivers and Restraints, 2015-2025
Figure 2.11 Theranostics: Market Drivers and Restraints, 2015-2025
Figure 3.1 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025
Figure 3.2 Applications of Nanotechnology in the Cardiovascular Therapeutic Area
Figure 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025
Figure 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025
Figure 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025
Figure 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025
Figure 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025
Figure 4.1 Nanomedicine - Segmented by Application
Figure 4.2 Proportions of Nano Products by Application, 2014
Figure 4.3 Proportions of Nano Products by Therapeutic Area, 2014
Figure 4.4 Abraxane Revenue Forecast ($bn), 2015-2025
Figure 4.5 Alimta Revenue Forecast ($bn), 2015-2025
Figure 4.6 Eligard Revenue Forecast ($bn), 2015-2025
Figure 4.7 Copaxone Revenue Forecast ($bn), 2015-2025
Figure 4.8 Rapamune Revenue Forecast ($bn), 2015-2025
Figure 4.9 Neulasta Revenue Forecast ($bn), 2015-2025
Figure 4.10 Cimzia Revenue Forecast ($bn), 2015-2025
Figure 4.11 AmBisome Revenue Forecast ($bn), 2015-2025
Figure 4.12 MIRCERA Revenue Forecast ($bn), 2015-2025
Figure 4.13 Pegasys Revenue Forecast ($bn), 2015-2025
Figure 4.14 Emend Revenue Forecast ($bn), 2015-2025
Figure 4.15 Renagel Revenue Forecast ($bn), 2015-2025
Figure 4.16 Ritalin Revenue Forecast ($bn), 2015-2025
Figure 5.1 Leading National Nanomedicine Markets by Share of Global Market (%), 2014
Figure 5.2 Leading National Nanomedicine Markets by Share of Global Market (%), 2019
Figure 5.3 Leading National Nanomedicine Markets by Share of Global Market (%), 2025
Figure 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.7 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 5.8 RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
Figure 7.1 Proportion of Products by Therapeutic Area in Clinical Trials, 2014
Figure 7.2 Products in Clinical Trials by Developmental Phase, 2014

【レポートのキーワード】

ナノメディシン、治療、用途、ナノ技術、医薬品、アブラキサン、ドキシル、製薬

★調査レポート[ナノメディシンの世界市場2015-2025] ( Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 / VGAIN5100107) 販売に関する免責事項
[ナノメディシンの世界市場2015-2025] ( Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 / VGAIN5100107) についてEメールでお問い合わせ
◆関連調査資料◆
  • 臨床試験アウトソーシングサービスの世界市場2015-2025
  • 自動車タイヤの世界市場2015-2025
  • 世界における主要な幹細胞技術企業分析2015-2025
  • ラテンアメリカの製薬市場2015-2025
  • グラフェンの世界市場予測2015-2025
  • 世界のコネクテッドカー市場2015-2025
  • 化粧品包装（パッケージ）の世界市場予測2015-2025
  • オイルサンドの世界市場2015-2025
  • 硬質プラスチック包装の世界市場2015-2025
  • 冷凍加工食品の世界市場予測2015-2025

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆